The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis. The gene discussed is CHIT1; the disease is metabolic dysfunction-associated steatohepatitis.